Antibiotic Potentiators Targeting SOS Induction
Antibiotic Potentiators Targeting SOS Induction
批准号:
7537576
负责人:
TIMOTHY J OPPERMAN
金额:
$30.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-20 至 2010-06-30
关键词:
AmpicillinAnimal ModelAntibiotic ResistanceAntibioticsBacteriaBacterial InfectionsBiological AssayCellsCharacteristicsCiprofloxacinClassClinicCollaborationsDNA DamageDNA RepairDNA biosynthesisDataDevelopmentDimethyl SulfoxideDoseDrug DesignEscherichia coliEvaluationEvolutionExhibitsFluoroquinolonesGenerationsGenesGoalsInfectionInhibitory Concentration 50InstitutesInvestigational New Drug ApplicationLeadLibrariesMassachusettsMolecular TargetMonobactamsMutationNoisePathway interactionsPharmaceutical ChemistryPharmaceutical PreparationsPhasePlayProductionProteinsPublic HealthPublishingQuinolonesRateReporterReportingResistanceResistance developmentRoleSOS ResponseSeriesSet proteinSignal TransductionSmall Business Technology Transfer ResearchSon of Sevenless ProteinsSpecific qualifier valueSpecificityStaphylococcus aureusStructure-Activity RelationshipTechniquesTechnologyTimeToxic effectTrimethoprimUnited States Food and Drug AdministrationVirulence FactorsWalkersbactericidebasebiological adaptation to stressclinically relevantdaydrug discoveryhigh throughput screeninginhibitor/antagonistinnovationnovelpreclinical studypreventresearch studysmall moleculetransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Several clinically important classes of antibiotics strongly induce the SOS response in bacteria. SOS defective bacteria are significantly more sensitive to quinolone, fluoroquinolone, and 2-lactam antibiotics than are wild type bacteria. Induction of the SOS response increases the evolution of antibiotic resistance and the horizontal transfer of virulence factors. Therefore, the SOS induction pathway is an important target for discovery of drugs that act as potentiators of clinically important antibiotics and reduce the evolution of antibiotic resistance. The overall goal of this STTR proposal is to discover and develop drugs that are potentiators of clinically relevant fluoroquinolones by specifically inhibiting induction of the SOS response. This approach represents an innovation in the way bacterial infections will be treated. These innovative drugs will increase the efficacy of existing clinically relevant antibiotics at low doses, prevent evolution of resistance and transmission of virulence factors. In Phase I of this STTR, we will identify inhibitors of SOS induction using a cell-based reporter assay in a high-throughput screen (HTS) of a diverse library of drug-like small molecules. We will evaluate these inhibitors for potency, specificity, and spectrum of activity using a series of secondary assays. The activity of the SOS inhibitors will be optimized in iterative rounds of medicinal chemistry and evaluation. Inhibitors that meet the criteria specified for secondary assays will be designated Validated Hits. Mechanism of Action (MOA) studies will be carried out for promising Validated Hits. In Phase II, Validated Hits with a confirmed MOA will be developed into Lead Compounds by optimizing their activity and specificity using rational drug design. The Specific Aims are as follows. Aim 1- Develop a cell-based reporter HTS for inhibitors of SOS induction. Aim 2-Screen a diverse compound library, identify, and confirm inhibitors of SOS induction. Aim 3-Validate confirmed SOS inhibitors using secondary assays and identify a validated Hit series. Aim 4-Determine mechanism of action of Validated Hits/Identify target. PUBLIC HEALTH RELEVANCE: Bacteria respond to environmental insults by producing proteins that increase their survival. Several antibiotics that are currently used to treat bacterial infections, such as ampicillin, amoxacillin, and ciprofloxacin, activate the production of a set of proteins collectively referred to as the SOS response. This important stress response plays a critical role in repairing DNA damage and increasing tolerance to DNA damaging agents. Bacteria that are unable to activate the SOS response are highly sensitive to the antibiotics listed above and are less likely to develop resistance. The goal of this project is to discover drugs that prevent SOS activation and increase the efficacy of several important antibiotics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Type 3 secretion system inhibitors to treat Pseudomonas aeruginosa keratitis
-
批准号:10484345
-
项目类别:
-
资助金额:$30.02万
-
财政年份:2022
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
Inhibitors of wall teichoic acid biosynthesis of Staphylococcus aureus
-
批准号:8423694
-
项目类别:
-
资助金额:$29.54万
-
财政年份:2012
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
Optimization of novel pyranopyridine efflux pump inhibitors
-
批准号:10227128
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2012
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
Inhibitors of wall teichoic acid biosynthesis of Staphylococcus aureus
-
批准号:8250668
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
Novel aryl-rhodanine inhibitors of Streptococcus mutans biofilms
-
批准号:8393306
-
项目类别:
-
资助金额:$16.82万
-
财政年份:2012
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
Optimization of novel pyranopyridine efflux pump inhibitors
-
批准号:9206472
-
项目类别:
-
资助金额:$74.26万
-
财政年份:2012
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
Optimization of novel pyranopyridine efflux pump inhibitors
-
批准号:9011499
-
项目类别:
-
资助金额:$78.31万
-
财政年份:2012
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
A NOVEL BIS-INDOLE COMPOUND AGAINST CATHETER COLONIZATION
-
批准号:8318570
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2011
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
A NOVEL BIS-INDOLE COMPOUND AGAINST CATHETER COLONIZATION
-
批准号:8200796
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2011
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
Antibiotic Potentiators Targeting SOS Induction
-
批准号:7658098
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2008
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
c-diGMP Signal Transduction Proteins are Biofilm Drug Targets
-
批准号:7156141
-
项目类别:
-
资助金额:$36.78万
-
财政年份:2006
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
THERAPEUTIC APPROACHES TO BIOFILM ANTIBIOTIC RESISTANCE
-
批准号:6993121
-
项目类别:
-
资助金额:$30.48万
-
财政年份:2005
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
Novel Therapies for BioFilm-Related Infections
-
批准号:6827934
-
项目类别:
-
资助金额:$2.1万
-
财政年份:2003
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
Novel Therapies for BioFilm-Related Infections
-
批准号:6690432
-
项目类别:
-
资助金额:$2.56万
-
财政年份:2003
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
Novel Therapies for BioFilm-Related Infections
-
批准号:6875496
-
项目类别:
-
资助金额:$71.0万
-
财政年份:2003
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
Novel Therapies for BioFilm-Related Infections
-
批准号:6881672
-
项目类别:
-
资助金额:$89.25万
-
财政年份:2003
-
负责人:TIMOTHY J OPPERMAN
-
依托单位:
海外基金